Globulin may bind in vivo or in vitro to erythrocytes (red blood cells). This may occur in Hemolytic Disease of the Fetus and Newborn (HDFN), in transfusion reactions, and in autoimmune hemolytic anemia. Hemo bioscience has received 510(k) clearance to manufacture complement control cells using a modified Fruitstone1 low ionic method. New lots are manufactured every 28 days and lot release is performed with a wide range of AHG reagents. Please contact us to receive information regarding pricing, shipping schedule and a sales brochure.